(PharmaNewsWire.Com, January 26, 2017 ) According to the report Transcatheter Aortic Valve Replacement (TAVR), published by Market Data Forecast, the global market is projected to reach USD 4.29 billion by 2021, at a CAGR of 18.50% from 2016 to 2021.
Transcatheter aortic valve replacement (TAVR) is described as minimally invasive procedure replaces the improper functioning aortic valves. TAVR offers an efficient valve replacement procedure as compared to open-heart surgery for the benefit of high risk patients. Transcatheter heart valve replacement systems are referred as cardiovascular devices replace the old and damaged valves. TAVR is used for the treatment of aortic valve disorders such as severe aortic stenosis, degeneration, & regurgitation.
Transcatheter Aortic Valve Replacement Market are integrated with valve frame (made of nitinol or stainless steel), valve leaflets material (made of bovine or cow heart tissue). These aortic valves are available with varied sizes (such as 14mm, 16mm, 18mm, 20mm, 22mm, & 29mm). TAVR is performed during different surgery methods such as transfemoral implantation (through the femoral artery), transapical implantation (through the apex of the heart), transaortic implantation (through the top of right chest), and transcaval implantation (through the femoral vein).
Growing adoption of minimally invasive therapies, increasing number of severe aortic stenosis disorder patients, rising number of clinical trials cardiovascular indications, and growing number of product launches in this market are driving the growth of global transcatheter aortic valve replacement (TAVR) market. In addition, rising technological advancements, increasing demand for minimally invasive catheter-based procedures as compared to conventional open heart therapies, and growing number of patients choosing an efficient & effective therapy with quick recovery are further propelling the growth of global transcatheter aortic valve replacement (TAVR) market.
Global market for transcatheter aortic valve replacement (TAVR) is segmented on the basis of surgery method, valve frame material, valve size, valve leaflets material, and end users
The key players in global transcatheter aortic valve replacement (TAVR) market such as, Edwards Lifesciences Corporation (U.S.), Medtronic, Inc. (Ireland), Boston Scientific Corporation (U.S.), Abbott Laboratories (U.S.), St. Jude Medical Inc. (U.S.), JenaValve Technology, Inc. (Germany), Symetis SA (Switzerland), Direct Flow Medical, Inc. (U.S.), Sorin Group (Italy), Meril Life Sciences India Pvt Ltd (India), and Braile Biomedica (Brazil).
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: